Gastrointestinal Cancer

>

Latest News

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer
High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

June 4th 2025

Fruquintinib plus chemotherapy and a PD-1 inhibitor elicited an ORR of 80.0% with all partial responses in patients with treatment-naïve gastric/GEJ cancer.

SCRT/Chemo Produce Positive Responses in Locally Advanced Rectal Cancer
SCRT/Chemo Produce Positive Responses in Locally Advanced Rectal Cancer

June 3rd 2025

Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer
Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer

June 2nd 2025

EBC-129 was well tolerated, with a safety profile consistent with other MMAE-based ADCs in patients with PDAC and other solid tumors.
EBC-129 Shows Early Activity in Advanced Pancreatic Ductal Adenocarcinoma

June 2nd 2025

Elraglusib Plus Chemo Enhances Survival Vs Chemo Alone in Metastatic PDAC
Elraglusib Plus Chemo Enhances Survival Vs Chemo Alone in Metastatic PDAC

June 1st 2025

Latest CME Events & Activities

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View More

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

View More

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

View More

<1
...
5354555657